Journal
JOURNAL OF DIABETES AND ITS COMPLICATIONS
Volume 30, Issue 7, Pages 1354-1359Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jdiacomp.2016.05.012
Keywords
Sitagliptin; Sulfonylurea; Albuminuria; DPP-4 inhibitors; Nephropathy
Categories
Funding
- Merck & Co., Inc., Kenilworth, NJ, USA
Ask authors/readers for more resources
Aim: To compare the change in urinary albumin to creatinine ratio (UACR) in type 2 diabetes (T2DM) patients with albuminuria who initiate sitagliptin to those who initiate a sulfonylurea (SU) as add-on to metformin monotherapy. Method: A cohort of T2DM patients with albuminuria (UACR >30 mg/g) who initiated sitagliptin or SU as add-on dual therapy to metformin between 2008 and 2014 was extracted from the computerized medical records of a large managed care organization in Israel. Patients with albuminuria and UACR measurements available at treatment initiation and 120-365 days afterwards were included. Propensity scores were calculated based on 17 factors, including demography, comorbidities, baseline levels of HbAlc, UACR, BMI, eGFR, and ACE/ARB use, and patients were matched in a 1:1 ratio. Changes in UACR were compared between the matched pairs using generalized estimating equations. Results: A total of 282 eligible pairs (sitagliptin:SU) were identified. During a mean follow-up of 9 months, median UACR changes were -35% (IQR = -73% to 5%) and -31% (IQR = -72% to 21%) in the sitagliptin and SU groups, respectively. Mean absolute HbAlc reductions among sitagliptin and SU groups were 0.9% and 1.0%, respectively. The magnitude of UACR reduction generally increased with greater magnitude of HbAlc reduction in both treatment groups. However, after controlling for HbAlc reduction and the interaction between HbAlc reduction and UACR reduction, sitagliptin users demonstrated a trend toward an increased likelihood of UACR reduction compared to SU users (odds ratio = 120; 95% confidence interval: 0.99-1.47, P = 0.063). Conclusion: Our results suggest that both sitagliptin and SU reduce albuminuria as an add-on therapy to metformin, but that sitagliptin may provide greater reductions in albuminuria independent of glycemic control when compared to SU. Larger population studies are required to further explore this. 2016 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available